补硒显著降低慢性自身免疫性甲状腺炎患者甲状腺自身抗体水平:一项系统评价与Meta分析
该系统评价纳入16项对照试验,评估补硒对慢性自身免疫性甲状腺炎(AIT)患者甲状腺自身抗体及免疫调节的影响。在左甲状腺素(LT4)治疗人群中,补硒3、6、12个月后TPOAb显著降低;未治疗人群仅3个月时TPOAb降低。补硒组报告不良事件的风险显著更高,证据质量普遍较低。
要点
- 补硒组报告不良事件的风险显著高于对照组(p=0.036)。
核心结论
- 补硒可降低LT4治疗的AIT患者3、6、12个月的血清TPOAb水平,以及未治疗AIT患者3个月的TPOAb水平。
- 这些效应是否与临床相关指标相关仍有待证实。
研究设计与样本
- 系统评价与Meta分析,检索获得3366条记录,最终纳入16项对照试验。
- 纳入标准为≥18岁AIT成人,比较补硒(联合或不联合LT4)与安慰剂和/或LT4。
- 采用随机效应模型的加权均数差(WMD)进行Meta分析,并使用I²评估异质性,采用GRADE评估证据质量。
主要发现
- 在LT4治疗人群中,TgAb在12个月时降低,但3个月和6个月时未降低。
- 在未治疗人群中,TgAb在3个月时降低,但6个月和12个月时未降低。
- 补硒组报告不良事件的风险显著高于对照组(p=0.036)。
关键数值与推荐
- 证据质量普遍评为低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据质量普遍评为低。
- 这些效应是否与临床相关指标相关仍有待证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selenium supplementation may decrease circulating thyroid autoantibodies in patients with chronic autoimmune thyroiditis (AIT), but the available trials are heterogenous. This study expands and critically reappraises the knowledge on this topic. METHODS: A literature search identified 3366 records. Controlled trials in adults (≥18 years of age) with AIT, comparing selenium with or without levothyroxine (LT4), versus placebo and/or LT4, were eligible. Assessed outcomes were serum thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) autoantibody levels, and immunomodulatory effects. After screening and full-text assessment, 16 controlled trials were included in the systematic review. Random-effects meta-analyses in weighted mean difference (WMD) were performed for 3, 6, and 12 months of supplementation in two different populations: one receiving LT4 therapy and one newly diagnosed and LT4-untreated. Heterogeneity was estimated using I2, and quality of evidence was assessed per outcome, using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines. RESULTS: In LT4-treated populations, the selenium group had significantly lower TPOAb levels after three months (seven studies: WMD = -271 [confidence interval (CI) -366 to -175]; p < 0.0001; I2 = 45.4%), which was consistent at six months (three studies) and 12 months (one study). TgAb decreased at 12 months, but not at three or six months. In LT4-untreated populations, the selenium group showed a decrease in TPOAb levels after three months (three studies: WMD = -512 [CI -626 to -398]; p < 0.0001, I2 = 0.0%), but not after 6 or 12 months. TgAb decreased at 3 months, but not at 6 or 12 months. Quality of evidence was generally assessed as low. Study participants receiving selenium had a significantly higher risk than controls of reporting adverse effects (p = 0.036). CONCLUSIONS: Selenium supplementation reduced serum TPOAb levels after 3, 6, and 12 months in an LT4-treated AIT population, and after three months in an untreated AIT population. Whether these effects correlate with clinically relevant measures remains to be demonstrated.
引用
- Wichman J, Winther KH, Bonnema SJ, et al. Selenium Supplementation Significantly Reduces Thyroid Autoantibody Levels in Patients with Chronic Autoimmune Thyroiditis: A Systematic Review and Meta-Analysis. Thyroid. 2016. PMID: 27702392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。